2nd Interstitial Lung Disease Drug Development Summit

Memo

With SSc-ILD on the cusp of regulatory approval following closely behind Pirfenidone’s breakthrough therapy designation to treat uILD earlier this year, and investment pouring across multiple ILD phenotypes, the window of therapeutic opportunity to develop clinically defining drugs to treat interstitial lung disease is well and truly open. The timely 2nd ILD Summit will siphon critical insights from experts at Pfizer, Genentech, Novartis, Boehringer Ingelheim and Pieris Pharmaceuticals to help you to catalyze a new wave of therapies against Scleroderma, Sarcoidosis, COP, CT-ILDs and more. With 3 unique days of dedicated scientific content - from discovering how to strategically optimize your approach to treating inflammatory vs fibrotic ILDs to learning how to leverage clinical trials to identify novel outcomes and investigating the transformative power of machine learning for ILD imaging - this is the perfect intensive crash course for experts across your team to get up to speed with the latest ILD developments. Join 20+ brand new speakers and 150+ drug developers from leading companies online to uncover the secrets behind developing industry defining ILD therapies, tailor the experience to meet your needs and supercharge your ILD drug development approach. Tickets https://go.evvnt.com/921955-2?pid=5569Brochure https://go.evvnt.com/921955-3?pid=5569 Prices:Conference Only - Academic USD 1699.00Conference + Exploring Biomarkers Workshop - Academic USD 2188.00Conference + Inhaled Drug Delivery Day - Academic USD 2397.00Conference Only - Service Provider USD 2599.00Conference + Exploring Biomarkers Workshop - Service Provider USD 3228.00Conference + Inhaled Drug Delivery Day - Service Provider USD 3497.00Conference Only - Drug Developer USD 2099.00Conference + Exploring Biomarkers Workshop - Drug Developer USD 2698.00Conference + Inhaled Drug Delivery Day - Drug Developer USD 2947.00 Speakers: Adam Byrne, Professor, Imperial College London, Cara Williams, Vice President & Head of Preclinical Biology: Inflammation & Immunology Research Unit, Pfizer, Carsten Ehrhardt, Professor of Pharmacy, Trinity College Dublin, Craig Conoscenti, Medical Expert ILD Respiratory Clinical Development & Medical Affairs, Boehringer Ingelheim, David Barber, Professor of Machine Learning, UCL, Dinesh Khanna, Professor, University of Michigan, Elizabeth Renzoni, Consultant Respiratory Physician, Honorary Senior Lecturer, Imperial College London, Eric White, Senior Clinical Program Lead, Boehringer Ingelheim, Farrell Simon, Vice President & Head of US Marketing, Trevi Therapeutics, Glenn Rosen, Chief Scientific Officer, Optikira & Biomotiv, Jason Laufer, Chief Executive Officer, Remedy Cell, Majd Mouded, Executive Director for BioMedical Research, Novartis, Margaret Neighbors, Principle Scientist, Genentech, Martin Kolb, Professor, McMaster University, Matt Bradley, Founder, Chairman, President, & Chief Technical Officer, SAJE Pharma, Nicolas Guisot, Research Fellow & Project Leader, Redx Pharma, Nina Patel, Director – Clinical Development & Medical Affairs ILD, Boehringer Ingelheim, Paolo Cameli, Pulmonologist, University of Siena, Peter Fernandes, Vice President & Chief Regulatory, Quality & Safety Officer, Bellerophon Therapeutics, Rohit Batta, Chief Scientific Officer, Vicore Pharma, Shane Olwill, Senior Vice President & Chief Development Officer, Pieris Pharmaceuticals, Shannon Turley, Vice President of Cancer Immunology Discovery, Genentech, Shervin Assassi, Director of the Division of Rheumatology, The University of Texas, Simon Walsh, Consultant Thoracic Radiologist, Machine Learning Scientist & Imaging Chair, Imperial College London, Steve Jones, President, EUIPFF, Tejaswini Kulkarni, Director of Interstitial Lung Disease Program, University of Alabama, Toby Maher, Director, Interstitial Lung Disease Program, USC, Vanessa Neins, Senior Scientist - Biology Lead Respiratory, Pieris Pharmaceuticals Date and Time: Starts: Mon, Mar 7, 22 ( 9:00 AM) and Ends: Wed, Mar 9, 22 ( 5:05 PM)